TAKE2 Licenses Nasopharyngeal Cancer Early Detection Technology from GRAIL

HONG KONG–(BUSINESS WIRE)–TAKE2 HEALTH LTD. (“TAKE2”), a healthcare technology company based in
Hong Kong, China, today announced that it has entered into a definitive
license agreement with GRAIL, Inc., for the exclusive worldwide rights
to an intellectual property portfolio for the early detection of NPC.
The company is co-founded by Professor Dennis Lo, Professor Rossa Chiu
and Professor Allen Chan of the Chinese University of Hong Kong. TAKE2
aims to be a key driver that makes the most disruptive healthcare
inventions widely accessible to the public in China and Asia.

TAKE2 will initially focus on the development and commercialization of
technologies that can allow the early detection of nasopharyngeal cancer
(NPC). Professor Lo and his team invented the NPC early detection
technologies, which were previously licensed to GRAIL. Professor Lo
conducted and published a landmark study which demonstrated that
circulating DNA analysis is useful for screening early asymptomatic NPC,
and his research was among the 10 ‘Notable Articles of 2017’ of The New
England Journal of Medicine.

“One mission of TAKE2 is to provide individuals a second chance in
health through the early detection of disease,” said Professor Lo. “Our
initial focus will be making our early detection technology for NPC
widely accessible to those who need it most. NPC is most prevalent in
China and the ASEAN countries, a region with a total population size of
over 2 billion, and is a deadly cancer as the majority of cases are
diagnosed at late stages. The creation of Take2 is thus both timely and
meaningful.”

About TAKE2

TAKE2 is a healthcare start-up which explores, invents, and builds
empowering platforms to harness the power of biomedical sciences and
informatics to deliver better healthcare solutions to individuals and
communities with actionable information and results. Headquartered in
Hong Kong, China, TAKE2 aims to be a key driver that makes the most
disruptive healthcare inventions widely accessible to the public in
China and Asia. For more information, please email to [email protected].

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early,
when it can be cured. GRAIL is focused on alleviating the global burden
of cancer by developing pioneering technology to detect and identify
multiple deadly cancer types early. The company is using the power of
next-generation sequencing, population-scale clinical studies, and
state-of-the-art computer science and data science to enhance the
scientific understanding of cancer biology, and to develop its
multi-cancer early detection blood test. GRAIL is located in Menlo Park,
California. It is supported by leading global investors and
pharmaceutical, technology, and healthcare companies. For more
information, please visit www.grail.com.

Contacts

Dennis Lo
[email protected]